Conclusion
For patients with BRCA1/2-mutated ovarian cancer with secondary
platinum-sensitive recurrence, the therapeutic effect of PARPi
monotherapy and platinum-based chemotherapy was equivalent. PARPi
monotherapy does not negatively affect the efficacy of subsequent
platinum-based chemotherapy after the progression of PARPi monotherapy
and could improve prognosis.